TNFRSF11A and breast carcinoma: Similarly, the induction of breast cancer by the co-administration of MPA and the carcinogenic agent 7,14-dimethylbenz[a]anthracene (DMBA) in RANK-deficient mice resulted in the delayed onset of mammary tumor development and increased survival rates [17].